The meeting serves as a crucial platform for analyzing surveillance data collected by the WHO Global Influenza Surveillance ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old. <li /> On track for launch in key European markets i ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 ...

The global mammalian transient protein expression market is on a robust growth trajectory, projected to reach USD 762.34 million in 2024 and expand at a CAGR of 5.5% over the next decade, ultimately ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic ...

Hyderabad (Telangana) [India], February 25 (ANI): Biological E Limited (BE) on Tuesday announced a strategic partnership with ...

Biological E partners with Bavarian Nordic to expand access to Chikungunya Vaccine in low- and middle-income countries.

Hyderabad-based Biological E. Limited (BE) is partnering with Danish firm Bavarian Nordic to expand access to the latter’s ...

Biological E (BE) has partnered with Bavarian Nordic to produce the Chikungunya vaccine, VIMKUNYA CHIKV VLP, for low and ...

The partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine ...

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries. COPENHAGEN, Denmark ...